Through court decisions and regulatory actions, Indian officials have pressed foreign-based multinationals for lower-cost drugs. These multinationals, however, have argued that Indian actions hinder their ability to do business selling innovative if costlier drugs.
“The upper socioeconomic segments can afford western products at western prices, but the middle class can benefit from innovative products tailored to their specific needs and pocketbooks,” Gunjan Bagla, managing director of Amritt, a Cerritos, CA, management advisory service that assists U.S. companies expanding into India, told GEN. “Some western companies are capable of and interested in addressing this segment while others are not.”
